The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 1, Issue 5, Pages e17-e17
Publisher
Springer Nature
Online
2011-05-13
DOI
10.1038/bcj.2011.16
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity
- (2010) C. J. V. Campbell et al. BLOOD
- Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
- (2010) N Chapuis et al. LEUKEMIA
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Targeting the Notch1 and mTOR pathways in a mouse T-ALL model
- (2009) K. Cullion et al. BLOOD
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia
- (2009) R. Crazzolara et al. BLOOD
- Expression of CD133 on leukemia-initiating cells in childhood ALL
- (2009) C. V. Cox et al. BLOOD
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD / SCID / IL-2Rγc−/−mice
- (2009) Ryohei Tanizaki et al. CANCER SCIENCE
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
- (2009) Cristian Bellodi et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib and beyond—exploring the full potential of targeted therapy for CML
- (2009) Alfonso Quintás-Cardama et al. Nature Reviews Clinical Oncology
- CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL
- (2008) Y Kong et al. LEUKEMIA
- Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
- (2008) N Misaghian et al. LEUKEMIA
- BCR-ABL-transformed GMP as myeloid leukemic stem cells
- (2008) Y. Minami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 promotes survival through translational control of Mcl-1
- (2008) J. R. Mills et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia
- (2008) D. Hong et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now